Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 647.19

+0.5%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (3311)	6/17/2021 12:16:59 PM
From: CuttingEdge Bio	Read Replies (1) of 3557

This is getting ridiculous now. What Porges is implying is that REGN needs 10x the dose to reach the same level of activity as BMY's molecule. For one, there is no actual evidence that that is true. So I don't know why it would be implied. 2. It would mean that REGN, somehow, created an inferior LAG3 antibody with poor drug properties (and went forward with it!) while BMY or its partner made a nice one. After all we have seen over the years about Regn's antibody capabilities, why would anyone harbor such a delusion like this? I think they know how to make an antibody.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next